Insider · CIK 0002123881
Lenaic Nathanael Teyssedou
Files at ADXN (Addex Therapeutics Ltd.). First filing -, latest -.
In brief
Lenaic Nathanael Teyssedou files SEC Form 4 as officer at ADXN (Addex Therapeutics Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lenaic Nathanael Teyssedou has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -37,770 | $0.00 | $0 | 565,138 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +37,770 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -59,530 | $0.00 | $0 | 543,378 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +59,530 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 592,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 572,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -65,620 | $0.00 | $0 | 537,288 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +65,620 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -90,529 | $0.00 | $0 | 512,379 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +90,529 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -208,974 | $0.00 | $0 | 393,934 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +208,974 | $0.00 | $0 | 602,908 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -100,485 | $0.00 | $0 | 502,423 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +100,485 | $0.00 | $0 | 602,908 | 39 d ago |
Questions about Lenaic Nathanael Teyssedou
Answered from the filings on this page, as of the latest one.
Is Lenaic Nathanael Teyssedou buying or selling?
Lenaic Nathanael Teyssedou has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lenaic Nathanael Teyssedou's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lenaic Nathanael Teyssedou has 0.
Where does Lenaic Nathanael Teyssedou file Form 4?
Lenaic Nathanael Teyssedou has filed Form 4 at ADXN (Addex Therapeutics Ltd.) as PRINCIPAL ACCOUNTING OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.